|
|
Vaccine Detail
|
PSA Prostate Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: PSA Prostate Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007149
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KLK3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Hannu et al., 2014)
- Detailed Gene Information: Click Here.
- KLK3
gene engineering:
- Description: This is for Prostate Cancer (NCT00015977). A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth (NCIT_C2497; Hannu et al., 2014).
|
| Host Response |
|
|
| References |
Hannu et al., 2014: Hannu K, Johanna M, Ulf-Håkan S. KLK-targeted Therapies for Prostate Cancer. EJIFCC. 2014; 25(2); 207-218. [PubMed: 27683469].
Heiser et al., 2002: Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. The Journal of clinical investigation. 2002; 109(3); 409-417. [PubMed: 11828001].
NCIT_C2497: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2497]
NCT00015977: [https://clinicaltrials.gov/ct2/show/NCT00015977]
|
|
